Sunesis Pharmaceuticals (SNSS) Posts Mixed Q4 Results

Sunesis Pharmaceuticals (NASDAQ: SNSS) reported Q4 EPS of ($0.02), $0.17 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $896 thousand versus the consensus estimate of $1.17 million.

For earnings history and earnings-related data on Sunesis Pharmaceuticals (SNSS) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Morgan Stanley Downgrades AutoNation Inc. (AN) to Equalweight
• Morgan Stanley Downgrades Group 1 Automotive Inc. (GPI) to Underweight